Insulatard

Insulin Human, the active ingredient in Insulatard, is an insulin presented as an injectable solution for subcutaneous administration. It is used to lower blood glucose levels in patients with type 1 and type 2 diabetes mellitus, providing basal insulin coverage to maintain glycaemic control.

GNH USA supplies Insulatard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Customers benefit from reliable cold‑chain logistics and dedicated technical support.

Insulatard, a long‑acting insulin analogue, is used in the management of diabetes mellitus. - Type 1 diabetes mellitus: provides basal insulin to control fasting glucose levels. - Type 2 diabetes mellitus: supplements endogenous insulin to achieve glycaemic targets. - Basal insulin therapy: maintains steady insulin levels between meals and overnight.

Adverse reactions may occur with any insulin therapy.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if meals are missed or dose is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight due to improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat at injection sites. - Edema: mild fluid retention, particularly in the lower extremities.

Serious or Rare Side Effects: - Severe hypoglycaemia with seizures or loss of consciousness. - Allergic reactions including anaphylaxis, urticaria, or angioedema. - Insulin antibody formation that may alter insulin action. - Lipohypertrophy leading to erratic insulin absorption. - Hypokalemia: low potassium levels in rare cases.

Use Insulatard with careful monitoring and appropriate patient education. - Blood glucose monitoring: check levels regularly to adjust dose as needed. - Dose adjustment during illness: reduce or increase dose based on carbohydrate intake and activity. - Caution in renal or hepatic impairment: may require dose modification. - Pregnancy and breastfeeding: only use if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin therapy can be affected by several concomitant medicines.

Major Interactions (Avoid): - Other insulin products: additive hypoglycaemic effect. - Sulfonylureas: increased risk of severe hypoglycaemia. - Meglitinides: additive glucose‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors: can potentiate insulin’s glucose‑lowering action. - Thiazide diuretics: may raise blood glucose levels. - Oral contraceptives: may slightly reduce insulin requirements.